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INTRODUCTION
The article follows men age 50-59 between 1999 and 2009
that were newly diagnosed with clinically localized prostate
cancer. They were then separated randomly into 3 different
groups including active surveillance, radiotherapy, and
radical prostatectomy. The purpose was to gauge the
effectiveness of treatments in terms of premature death. The
importance of this study was to evaluate for an incredibly
pressing concern of prostate cancer throughout not only the
United States, but worldwide. There are uncertainties when it
comes to the way prostate cancer is diagnosed and its
correlation to treatment outcomes. This study (a two-part
study initially published in 2014) found low cancer specific
mortality regardless of treatment.2 The study referred to its
initial randomized trial which focused more on methodology
of diagnosis as well as other literature with randomized trials
comparing prostatectomy with active surveillance or
radiotherapy. These ranged from randomized controlled
studies to patient reported outcomes. The active monitoring
group differs from previous studies incorporating “watchful
waiting” such as the Scandinavian Prostate Cancer Group
Study Number 4 and the U.S. Prostate Cancer Intervention
versus Observation Trial (PIVOT).3,4,5 In the current study
patients were assessed for changes in PSA levels and as a
result clinical management could be modified whereas in the
2 latter studies mentioned no intervention was provided.3,4,5
Despite the differences among the trials PIVOT concluded
that there was not a significant difference in cancer-specific
mortality rates between watchful waiting and radical
prostatectomy. However, amongst the Scandinavian trials it
was concluded that radical prostatectomy helped to reduce
cancer-specific mortality, but did not have a difference
between overall survival.3,6 Adding in the perspective of
prostatectomy versus radiotherapy, a meta-analysis
completed found increased overall risk of mortality, both non
cancer-specific and cancer-specific.7 Per a retrospective
study there was an insignificant difference found amongst
prostatectomy and radiotherapy.8

RESULTS

RESULTS

Table 2. Deaths from Prostate Cancer, According to
Subgroup.

Figure 1. Randomization, Treatment, and Follow-up.A
total of 88% of the men assigned to active monitoring, 71% of
the men assigned to surgery, and 74% of men assigned to
radiotherapy received the assigned treatment within 9
months after randomization. A total of 14 patients were lost to
follow-up for secondary outcomes, but data on deaths were
captured for all participants.

METHODS
This study was a prospective trial that compared active
monitoring, radical prostatectomy, and external-beam
radiotherapy for the treatment of localized prostate cancer. A
total of 82,429 men 50 to 69 years of age received a PSA
test between 1999 and 2009. Of that 2664 received the
diagnosis of clinically localized prostate cancer, and 1643
agreed to undergo randomization. After randomization 545
men were active monitoring, 545 underwent radiotherapy,
and 553 men underwent surgery. The goal of randomization
was to ensure the groups were made to be as similar in
demographics as possible with respect to age, Gleason
score, mean baseline from the first biopsy and PSA test.
Prostate-cancer mortality at a median of 10-year follow-up
was the primary outcome. The secondary outcome included
the rates of disease progression, metastases, and all deaths.
A total of 14 patients were lost to follow up for secondary
outcomes, but data on deaths were captured for all
participants. Sensitivity analyses excluded men that were
recruited during the feasibility phase or that included deaths
that were judged to be possibly due to prostate cancer. Men
were also excluded based on PSA test results from the initial
randomized control trial.
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CONCLUSIONS
The results found that of the 1643 men included, 14 were lost
to follow up due to outcomes during the follow up period, but
were still included in the study. They found secondary issues
within the study where 291 of the active monitoring group
ended up receiving some sort of radical treatment, which
included surgery and/or radiotherapy. Of the prostatectomy
group, 6 had to receive some sort of radiotherapy 1-year post
surgery. Of the radiotherapy group, 3 had to undergo savage
prostatectomy, and 15 received additional treatment. They
determined that 7-8 of the deaths in the active surveillance
group were prostate cancer specific, 3-5 in the surgery
group, and 4 in the radiotherapy group. Survival specific to
prostate cancer was determined to be around 98.8% in all
groups with an insignificant difference between the groups.
204 out of the total men were found to have disease
progression including metastasis (46 in the surgery, 112 in
the active surveillance, and 46 in the radiotherapy group).
There were minimal complications reported post treatment
although there were 3 deaths determined to be unrelated to
prostate cancer in the radiotherapy group. Numbers needed
to treat were determined to be 27 men for prostatectomy for
1 avoiding metastatic disease and 33 with radiotherapy. If
combined the number lowers to 9 men. The author
concluded that amongst all three treatment groups there was
no significant difference in prostate-cancer related deaths
over a 10-year span post intervention. However, it found that
prostatectomy and radiotherapy were associated with lower
incidences of progressing disease as opposed to the active
monitoring group. The long-term effects of intervention still
need to be evaluated to form a more educated and evidencebased decision on treatment. One factor not incorporated or
considered in the study was quality of life for which the
author appears to want to follow up on in future studies. The
study was limited in not considering quality of life or the
specific outcomes post-surgical or radiotherapy. With the
smaller sample size and the sample being solely out of the
UK certain factors such as if there are any differences in the
prostate cancer seen in the UK versus anywhere else in the
world was not addressed. The study and the previous
randomized trial can help to try and establish the benefit of
PSA testing in diagnosis of prostate cancer regarding overall
outcomes.
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